Skip to main content

Table 3 Baseline and post-treatment EORTC QLQ-C15-PAL scores

From: Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide

EORTC QLQ-C15-PAL scalea

Octreotide (N = 52)

mean scores (95% CI)

Placebo (N = 54)

mean scores (95% CI)

Baseline

Post-treatment

p-value

Baseline

Post-treatment

p-value

Overall quality of lifeb

22.08 (14.32, 29.85)

n = 40

30.81 (22.57, 39.05)

n = 33

0.205

31.48 (22.26, 40.70)

n = 36

32.22 (21.27, 43.18)

n = 30

0.778

Physical functioningb

27.69 (19.69, 35.69)

n = 39

32.44 (22.51, 42.36)

n = 30

0.204

31.17 (22.80, 39.53)

n = 40

30.00 (19.70, 40.27)

n = 30

0.831

Emotional functioningb

57.65 (47.35, 67.94)

n = 36

71.80 (60.78, 82.82)

n = 26

0.059

55.25 (45.26, 65.24)

n = 35

63.22 (50.20, 76.25)

n = 29

0.074

Fatiguec

74.09 (67.21, 80.97)

n = 39

71.88 (63.37, 80.40)

n = 32

0.107

74.10 (67.84, 80.35)

n = 39

71.88 (60.27, 83.48)

n = 32

0.965

Nausea & vomitingc

73.18 (62.34, 84.01)

n = 41

40.70 (27.56, 53.83)

n = 34

0.001

60.53 (50.55, 70.51)

n = 38

35.95 (23.63, 48.26)

n = 32

0.016

Painc

60.16 (49.33, 71.00)

n = 41

43.94 (32.23, 55.65)

n = 33

0.007

55.42 (45.01, 65.83)

n = 40

42.93 (30.48, 55.38)

n = 33

0.026

Dyspnoeac

40.65 (29.74, 51.56)

n = 41

32.32 (21.88, 42.76)

n = 33

0.077

36.75 (27.89, 45.62)

n = 39

27.08 (14.34, 39.83)

n = 32

0.008

Insomniac

45.83 (34.59, 57.08)

n = 40

33.33 (22.28, 44.39)

n = 33

0.013

46.67 (34.89, 58.44)

n = 40

47.92 (32.67, 63.16)

n = 32

0.868

Appetite lossc

74.17 (62.98, 85.36)

n = 40

56.25 (43.50, 69.00)

n = 32

0.034

82.05 (74.27, 89.83)

n = 39

57.58 (43.63, 71.52)

n = 33

0.002

Constipationc

67.50 (56.05, 78.95)

n = 40

50.00 (36.19, 63.81)

n = 34

0.027

67.50 (56.31, 78.69)

n = 40

52.53 (38.35, 66.71)

n = 33

0.027

  1. Bolded numbers indicate statistically significant differences
  2. HrQoL Health-related quality of life
  3. amean unadjusted within-group paired differences between baseline and post-treatment scores were analysed using the Wilcoxon Signed Rank test. b higher scores represent better outcomes; c higher scores represent greater symptom burden